|
Fig. 1. EphrinB1 interacts with Rab11fip5. (A) Co-IP was performed using stage-11 embryos injected with GFP-Rab11fip5 RNA (1 ng) and ephrinB1-HA (300 pg), ephrinB2-HA (500 pg) or ephrinB3-HA RNAs (300 pg). (B) Spatial expression pattern of Rab11fip5 and ephrinB1was analyzed using WISH at stage 28 with probes for Rab11fip5, ephrinB1 or ephrinB2. (C) HCR analysis was performed with anti-ephrinB1 or 2 and Rab11fip5 probe sets. The magnified images do not include DAPI for clarity. White arrows indicate the telencephalon. Scale bars: 200 µm.
|
|
Fig. 2. Interaction domain mapping between ephrinB1 and Rab11fip5. (A) Schematic of ephrinB1-WT or deletion mutants lacking 4, 10 or 19 amino acids from the C terminus. Co-IP was performed using stage-11 embryos injected with GFP-Rab11fip5 RNA (1 ng) and ephrinB1 deletion mutants (300 pg each) as indicated. The PDZ binding motif is in red. (B) Schematic of Rab11fip5-WT or deletion mutants lacking: the regions C-terminal to C2 (C2), C2 (δC2), the linker region 1 or 2 (δL1 or δL2), or the RBD domain (δRBD). Co-IP assay was performed using stage-11 embryos injected with ephrinB1-HA RNA (300 pg) and Rab11fip5 deletion mutants (1 ng each).
|
|
Fig. 3. Rab11fip5 interacts with ephrinB1 through GTP-bound Rab11. (A) Co-IP assay was performed using stage-11 embryos injected with V5-Rab11fip5 RNA (1 ng) and GFP-Rab5, 7, 9 and 11 (1 ng each). (B) Co-IP assay was performed using stage-11 embryos injected with V5-Rab11fip5 RNA (1 ng) and GFP-Rab11-WT, dominant negative mutant (SN) or constitutively active mutant (QL) (1 ng each). (C) Co-IP assay was performed using stage-11 embryos injected with ephrinB1-HA RNA (300 pg) and GFP-Rab11-WT, SN or QL (1 ng each), as indicated. Schematic (top) shows Rab11fip5-WT or Rab11fip5-I603E mutant. (D) Co-IP assay using stage-11 embryos injected with GFP-Rab11 RNA (1 ng) and V5-Rab11fip5-WT or Rab11fip5-I603E mutant (1 ng each). (E) Co-IP assay was performed using stage-11 embryos injected with ephrinB1-HA RNA (300 pg) and GFP-Rab11fip5-WT or Rab11fip5-I603E mutant (1 ng each). (F) Co-IP assay was performed using stage-11 embryos injected with ephrinB1-HA RNAs (300 pg) and GFP-Rab11fip5 (1 ng) along with GFP-Rab11-WT, SN or QL (1 ng each). (G) Immunostaining was performed with ectodermal explants from stage-11 embryos injected with ephrinB1-HA (300 pg), GFP-Rab11fip5 (1 ng) and Flag-Rab11-SN (1 ng) as indicated. White arrows denote the colocalization of ephrinB1 and Rab11fip5-WT. Histogram depicts the percentage of ephrinB1 puncta colocalized with Rab11fip5 (n=16). Data are mean±s.d. of three individual experiments. ****P<0.0001 (two-tailed unpaired t-test). Scale bars: 20 µm.
|
|
Fig. 4. Knockout of Rab11fip5 reduces developing telencephalon size and ephrinB1 expression levels. (A) Cas9 protein alone or Cas9 with Rab11fip5 sgRNA along with membrane-RFP RNAs (100 pg) were injected into one blastomere of tubb2b: GFP transgenic embryos at the two-cell stage. Images were taken at stage 45 under fluorescent stereomicroscopy. Yellow dotted lines indicate telencephalon borders. White arrows indicate injected side. Left panels shows magnification of boxed areas in right panels. (B) Brains were dissected from Rab11fip5 KO tadpoles at stage 45. Immunostaining was performed with anti-ephrinB1 antibodies. Insets show red fluorescent protein (RFP), indicating injected side. Histograms depict relative telencephalon size (n=15; left) and endogenous ephrinB1 levels (n=24; right) compared with uninjected telencephalon. Data are mean±s.d. from three individual experiments. Box plots shows the median values (middle bars) and first to third interquartile ranges (boxes); whiskers indicate minimum/maximum; dots indicate individual data points; asterisks indicate significant difference. ****P<0.0001 (two-tailed unpaired t-test). Scale bars: 200 µm.
|
|
Fig. 5. Rab11fip5 regulates ephrinB1 recycling. (A) RNAs were injected into two D1 blastomeres at the eight-cell stage as indicated. Embryos were harvested at 5, 10 and 15 h after injection and western blot analysis was performed. Histogram depicts relative ephrinB1 levels at 15 h post-injection (n=4). (B) RNAs were injected into two D1 blastomeres at the eight-cell stage as indicated. Ectodermal explants were dissected at stage 11 and then membrane-ephrinB1 was stained using Snap-tag substrate. Live cell images were taken at 0 h and 4 h post-Snap-staining. White arrows denote the fluorescent labeled membrane Snap-ephrinB1. Histogram shows relative membrane ephrinB1 levels (n=8). Left panels shows magnification of boxed areas in right panels. (C) MOs and RNAs as indicated were injected into two D1 blastomeres in eight-cell-stage embryos. Five brains were harvested in each group at stage 45 and western blot analysis performed using anti-ephrinB1 and anti-V5 antibodies. β-Actin was used as a loading control. Histogram shows relative membrane-bound ephrinB1 levels (n=4). Data are mean±s.d. of three individual experiments. *P<0.05, ****P<0.0001 [one-way ANOVA (Dunnett's multiple comparisons test)]. ns, no statistical differences between the groups. Scale bars: 10 µm.
|
|
Fig. 6. MO-mediated knockdown of Rab11fip5 reduces ephrinB1 levels, causes reduction in telencephalon size and suppresses proliferation. (A) MOs (4 ng) and RNAs (200 pg) as indicated were injected into one D1 blastomere of tubb2b: GFP transgenic embryos at the eight-cell stage. Images were taken at stage 45 using fluorescent stereomicroscopy. Yellow dotted lines indicate telencephalon borders. White arrows indicate injected side. Left panels shows magnification of boxed areas in right panels. (B) MOs (4 ng) and RNAs (200 pg) were injected into one D1 blastomere at the eight-cell stage as indicated. Brains were dissected at stage 45 and immunostaining performed using anti-ephrinB1 and phospho-histone H3 antibodies. Insets show red fluorescent protein (RFP), indicating injected side, and DAPI. (C) Histograms show relative telencephalon size (left), ephrinB1 expression levels (right) and phospho-histone H3 levels (middle) compared with uninjected telencephalons (n=32). Data are mean±s.d. from three individual experiments. Box plots shows the median values (middle bars) and first to third interquartile ranges (boxes); whiskers indicate minimum/maximum; dots indicate individual data points; asterisks indicate significant difference. ****P<0.0001 [one-way ANOVA (Dunnett's multiple comparisons test)]. ns, no statistical differences between the groups. Scale bars: 200 µm.
|
|
Fig. 7. Overexpression of ephrinB1 rescues Rab11fip5 knockdown defects. (A) Schematic of NTB-membrane GFP and NTB-ephrinB1-HA clones. (B) MOs (4 ng) and NTB constructs (50 pg) were injected into one D1.1 blastomere at the 16-cell stage as indicated. Brains were dissected at stage 35 and immunostaining performed using anti-ephrinBs and phospho-histone H3 antibodies. In the NTB panels, overexpressed ephrinB1-HA was stained with anti-HA-Alexa Fluor 488, whereas membrane GFP was stained with anti-GFP-Alexa Fluor 488. Yellow dotted lines indicate telencephalon borders. Histograms show relative telencephalon size (left) and phospho-histone H3 levels (right) compared with uninjected telencephalons (n=9). Data are mean±s.d. from three individual experiments. Box plots shows the median values (middle bars) and first to third interquartile ranges (boxes); whiskers indicate minimum/maximum; dots indicate individual data points; asterisks indicate significant difference. ****P<0.0001 [one-way ANOVA (Dunnett's multiple comparisons test)]. ns, no statistical differences between the groups. Scale bars: 200 µm.
|
|
Figure S1. Screening of the novel ephrinB2 binding proteinsusing mass spectrometric analysis. (A) RNAs of ephrinB2-HA (400pg) were injected into one-cell stage embryos. Co-immunoprecipitation (Co-IP) and mass spectrometric analysis were performed at stage 13. (B) the table indicates a number of possible ephrinB2 binding proteins in the indicated categories.
|
|
Figure S2. Protein sequence alignment of ephrinBs. (a) Sequence alignment of three ephrinB subfamily members. ( B) Sequence alignment of intracellular domain of ephrinB1 and ephrinB2 in pink.
|
|
Figure S3. Co-localization of Rab11 and Rab11fip5 is dependent on their interaction. Immuno-staining was performed with ectodermal explants dissected from stage 8 embryos injected wth GFP-Rab11 (250pg), V5-Rab11fip5-WT (1ng), and V5-Rab11fip5-I603E (1ng) as indicated. Scale bar, 10um.
|
|
Figure S4. Hypervariable domain (HVD) in Rab11 is required for an interaction with ephrinB. Schematic represent ation of the domain structure for Rab11. Co-immunoprecipation assay (Co-IP) was performed using embryos (stage 11) injected with ephrinB1-HA ( 300pg) and Rab11 deletion mutants ( 1ng each) as indicated. a: Alpha-helix, B: Beta-sheet
|
|
Figure S5. Rab11 activity affects co-localization of Rab11 and Rab11fip5. Immuno-staining was performed with ectodermal explants dissected from stage 8 embryos injected with ephrinB1- HA (300pg), V5-Rab11fip5-WT (1ng), and Rab11-WT, SN, or QL (1ng) as indicated. White arrows denote the colocalization of Rab11 and Rab11fip5-WT. Scale bar, 10μm. Histogram depicts the percentage of ephrinB1 puncta co-localized with Rab11fip5 in the ectodermal cells (n=15). Quantification with one-way ANOVA (Dunnett’s multiple comparisons test), ****p<0.0001. Data represent the mean ± S.D. of three individual experiments. * p < 0.05, **** p < 0.0001, ns: no statistical differences between the groups.
|
|
Figure S6. Rab11fip5 knockout using CRSPR/Cas9. Genomic sequences of the first axon of the Rab11fip5 gene. The direct sequencing of PCR amplicons (DSP) shows that several nucleotides were removed in the Cas9 and Rab11fip5 sgRNA injected F0 embryos. A start codon (red), PAM sequences (yellow), Rab11fip5 sgRNA target sequences (green) and gray highlights indicate 5'UTR and intron.
|
|
Figure S7. Immunostaining with ephrinB antibody. MOs and membrane-RFP were injected into one D1.1 blastomere at the 16-cell as indicated. Brains were dissected at stage 45 and immunostaining performed using anti-ephrinB antibody. The white indicate arrows indicated injected side. Scale bar, 200um.
|
|
Figure S8. Rab11 activity affects exogenously expressed ephrinB1 levels via Rab11fip5. Schematic representation of experimental procedure. RNAs were injected into two D1 blastomeres at the 8-cell stage as indicated. Embryos were harvested at 5, 10, 15 hours after injection and Western blot analysis was performed. Histogram depicts relative ephrinB1 leveles at 15 hours post-injection ( n=4) Qunatificatoi with one-way ANOVA (Dunnett's multiple comparison test) ****p<0.0001. Data represent the mean +- S.D. of three individual experiments. *p<0.05, *** p< 0.0001, ns: no statistical difference between the groups.
|
|
Figure S9. Rab11 activity affects ephrinB1 recycling through Rab11fip5. Schematic representation of experimental procedure. RNAs were injected into two D1 blastomeres at the 8-cell stage as indicated. Ectodermal explants were dissected at stage 11 an dthen membrane ephrinB1 was stained using Snap-tag substrate ( non cell permeable, Snap=surface TM 647). Live cell images were taken at 0 hour and 4 hours post-Snap-staining. Scale bar, 10um. Hiistogram depicts relative ephrinB1 levels at at 0 hour and 4 hours post- injection ( n=10). Quantification with one-way ANOVA (Dunnett's multiple comparison test) ****p<0.0001. Data represent the mean +- S.D. of three individual experiments. *p<0.05, *** p< 0.0001, ns: no statistical difference between the groups.
|
|
Figure S10. RaB11fip5 morpholino olios. Rab11fib5 MO targets the translational start region as indicated. Western blot analysis shows that Rab11fip5 MO efficiently blocks exogeneous WT- Rab11fip5 expression whereas the expression of the morpholino resistent MoR-Rab11fip5 is not affected by the Rab11fip5 MO.
|
|
Figure S11. Knockdown of Rab11fip5 did not reduce ephrinB1 mRNA expression. Rab11fip5 MOs were injected into two D1 blastomeres at the 8-cell stage as indicated. Brains were dissected at stage 45 and RT-qPCR analysis was performed. Quantification with unpaired t test, two-tailed (n=3) . Data represent the mean +- SD of the three experiments. *p=0.0181.
|
|
Figure S12. Knockdown of Rab11fib5 did not affect early brain specification. MOs and membrane-RFP were injected into one D1.1 blastomere at the 16-0cell stage as indicated. Expression of early brain specification genes were analyses using WISJ at stage 30 with probes for BF-1, OTX2 or PAX6. The black arrows indicate uninjected control side and the red arrows indicate injected side. Scale bar, 200um
|
|
Figure S13. Knockdown of Rab11fip5 did not induce apoptosis in developing telencephalon.
MOs (4ng) along with membrane-RFP (100pg) or p53 RNAs (50pg) were injected into one D1 blastomere at the 8-cell stage as indicated. Brains were dissected at stage 30 (A) or stage 45 (B) and immunostaining performed using anti-Cleaved caspase-3 and phospho-Histone H3 antibodies. Overexpression of p53 is used as a positive control. Scale bar, 200μm. Histograms depict relative Cleaved caspase-3 positive cell numbers compared with uninjected telencephalons (n=12). Quantification with one-way ANOVA (Dunnett’s multiple comparisons test), p = 0.7218. Data represent the mean ± S.D. of three individual experiments. ns: no statistical differences between the groups.
|
|
rab11fip5 (RAB11 family interacting protein 5 (class 1) ) gene expression in X. laevis embryo at NF stage 28, assayed via in situ hybridization, anterior view, dorsal up.
|
|
rab11fip5 (RAB11 family interacting protein 5 (class 1) ) gene expression in X. laevis embryo at NF stage 28, assayed via in situ hybridization, lateral view, anterior left, dorsal up.
|
